Advertisement

The Editor's Roundtable: Closing the Clinical Practice Gap—Using Evidence-Based Treatments for Managing Lipids

      This activity is supported by an educational grant from Merck & Co., Inc., Whitehouse Station, New Jersey.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lloyd-Jones D.
        • Adams R.
        • Carnethon M.
        • De Simone G.
        • Ferguson T.B.
        • Flegal K.
        • Ford E.
        • Furie K.
        • Go A.
        • Greenlund K.
        • Haase N.
        • Hailpern S.
        • Ho M.
        • Howard V.
        • Kissela B.
        • Kittner S.
        • Lackland D.
        • Lisabeth L.
        • Marelli A.
        • McDermott M.
        • Meigs J.
        • Mozaffarian D.
        • Nichol G.
        • O'Donnell C.
        • Roger V.
        • Rosamond W.
        • Sacco R.
        • Sorlie P.
        • Stafford R.
        • Steinberger J.
        • Thom T.
        • Wasserthiel-Smoller S.
        • Wong N.
        • Wylie-Rosett J.
        • Hong Y.
        • American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics—2009 update
        A report from the American Heart Association Statistics Committee and Stroke Statistics Committee.
        Circulation. 2009; 119: e1-e161
        • Kannel W.B.
        The Framingham Study: historical insight on the impact of cardiovascular risk factors in men versus women.
        J Gend Specif Med. 2002; 5: 27-37
        • Tsimikas S.
        • Willerson J.T.
        • Ridker P.M.
        C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients.
        J Am Coll Cardiol. 2006; 47: C19-C31
        • Danesh J.
        • Collins R.
        • Appleby P.
        • Peto R.
        Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies.
        JAMA. 1998; 279: 1477-1482
        • Danesh J.
        • Kaptoge S.
        • Mann A.G.
        • Sarwar N.
        • Wood A.
        • Angleman S.B.
        • Wensley F.
        • Higgins J.P.
        • Lennon L.
        • Eiriksdottir G.
        • Rumley A.
        • Whincup P.H.
        • Lowe G.D.
        • Gudnason V.
        Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review.
        PLoS Med. 2008; 5: e78
        • Aleksic N.
        • Wang Y.W.
        • Ahn C.
        • Juneja H.S.
        • Folsom A.R.
        • Wu K.K.
        Assessment of coronary heart disease risk by combined analysis of coagulation factors.
        Atherosclerosis. 2008; 198: 294-300
        • Humphrey L.L.
        • Fu R.
        • Rogers K.
        • Freeman M.
        • Helfand M.
        Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis.
        Mayo Clin Proc. 2008; 83: 1203-1212
        • Faeh D.
        • William J.
        • Yerly P.
        • Paccaud F.
        • Bovet P.
        Diabetes and pre-diabetes are associated with cardiovascular risk factors and carotid/femoral intima-media thickness independently of markers of insulin resistance and adiposity.
        Cardiovasc Diabetol. 2007; 6: 32
        • Simon A.
        • Chironi G.
        • Levenson J.
        Comparative performance of subclinical atherosclerosis tests in predicting coronary heart disease in asymptomatic individuals.
        Eur Heart J. 2007; 28: 2967-2971
        • Stamler J.
        • Wentworth D.
        • Neaton J.D.
        Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).
        JAMA. 1986; 256: 2823-2888
        • Pekkanen J.
        • Linn S.
        • Heiss G.
        • Suchindran C.M.
        • Leon A.
        • Rifkind B.M.
        • Tyroler H.A.
        Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease.
        N Engl J Med. 1990; 322: 1700-1707
        • Scandinavian Simvastatin Survival Study
        Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
        Lancet. 1994; 344: 1383-1389
        • Shepherd J.
        • Cobbe S.M.
        • Ford I.
        • Isles C.G.
        • Lorimer A.R.
        • MacFarlane P.W.
        • McKillop J.H.
        • Packard C.J.
        • West of Scotland Coronary Prevention Study Group
        Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
        N Engl J Med. 1995; 333: 1301-1307
        • Sacks F.M.
        • Pfeffer M.A.
        • Moye L.A.
        • Rouleau J.L.
        • Rutherford J.D.
        • Cole T.G.
        • Brown L.
        • Warnica J.W.
        • Arnold J.M.
        • Wun C.C.
        • Davis B.R.
        • Braunwald E.
        The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
        N Engl J Med. 1996; 335: 1001-1009
        • Heart Protection Study Collaborative Group
        MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial.
        Lancet. 2002; 360: 7-22
        • Shepherd J.
        • Blauw G.J.
        • Murphy M.B.
        • Bollen E.L.
        • Buckley B.M.
        • Cobbe S.M.
        • Ford I.
        • Gaw A.
        • Hyland M.
        • Jukema J.W.
        • Kamper A.M.
        • Macfarlane P.W.
        • Meinders A.E.
        • Norrie J.
        • Packard C.J.
        • Perry I.J.
        • Stott D.J.
        • Sweeney B.J.
        • Twomey C.
        • Westendorp R.G.
        • PROSPER Study Group
        Prospective study of pravastatin in the elderly at risk.
        Lancet. 2002; 360: 1623-1630
        • Sever P.S.
        • Dahlöf B.
        • Poulter N.R.
        • Wedel H.
        • Beevers G.
        • Caulfield M.
        • Collins R.
        • Kjeldsen S.E.
        • Kristinsson A.
        • McInnes G.T.
        • Mehlsen J.
        • Nieminen M.
        • O'Brien E.
        • Ostergren J.
        • ASCOT investigators
        Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
        Lancet. 2003; 361: 1149-1158
        • Gordon T.
        • Castelli W.P.
        • Hjortland M.C.
        • Kannel W.B.
        • Dawber T.R.
        High density lipoprotein as a protective factor against coronary heart disease.
        Am J Med. 1977; 62: 707-714
        • Wilson P.W.
        • D'Agostino R.B.
        • Levy D.
        • Belanger A.M.
        • Silbershantz H.
        • Kannel W.B.
        Prediction of coronary heart disease using risk factor categories.
        Circulation. 1998; 97: 1837-1847
        • Austin M.A.
        • Hokanson J.E.
        • Edwards K.L.
        Hypertriglyceridemia as a cardiovascular risk factor.
        Am J Cardiol. 1998; 81: 7B-12B
        • Friedewald W.T.
        • Levy R.I.
        • Fredrickson D.S.
        Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
        Clin Chem. 1972; 18: 499-502
        • Frost P.H.
        • Havel R.J.
        Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy.
        Am J Cardiol. 1998; 81: 26B-31B
        • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
        Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
        Circulation. 2002; 106: 3143-3421
        • Hyre A.D.
        • Muntner P.
        • Menke A.
        • Raggi P.
        • He J.
        Trends in ATP-III–defined high blood cholesterol prevalence, awareness, treatment, and control among US adults.
        Ann Epidemiol. 2007; 17: 548-555
        • Cullen M.W.
        • Stein J.H.
        • Gangnon R.
        • McBride P.E.
        • Keevil J.G.
        National improvements in low-density lipoprotein cholesterol management of individuals at high coronary risk: National Health and Nutrition Examination Survey, 1999 to 2002.
        Am Heart J. 2008; 156: 284-291
        • Ghandehari H.
        • Kamal-Bahl S.
        • Wong N.D.
        Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003–2004.
        Am Heart J. 2008; 156: 112-119
        • Grigore L.
        • Norata G.D.
        • Catapano A.L.
        Combination therapy in cholesterol reduction: focus on ezetimibe and statins.
        Vasc Health Risk Manag. 2008; 4: 267-278
      1. Profile of the Framingham Heart Study.
        (Accessed December 31, 2008)
        • LaRosa J.
        • Grundy S.M.
        • Kastelein J.J.
        • Kostis J.B.
        • Greten H.
        • Treating to New Targets (TNT) Steering Committee and Investigators
        Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the Treating to New Targets [TNT] study).
        Am J Cardiol. 2007; 100: 747-752
      2. NCEP guidelines.
        (Accessed December 22, 2008)
        • Kotowski I.K.
        • Pertsemlidis A.
        • Luke A.
        • Cooper R.S.
        • Vega G.L.
        • Cohen J.C.
        • Hobbs H.H.
        A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.
        Am J Hum Genet. 2006; 78: 410-422
        • Cohen J.C.
        • Boerwinkle E.
        • Mosley Jr, T.H.
        • Hobbs H.H.
        Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.
        N Engl J Med. 2006; 354: 1264-1272
        • Crouse III, J.R.
        • Raichlen J.S.
        • Riley W.A.
        • Evans G.W.
        • Palmer M.K.
        • O'Leary D.H.
        • Grobbee D.E.
        • Bots M.L.
        • METEOR Study Group
        Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.
        JAMA. 2007; 297: 1344-1353
        • Smilde T.J.
        • van Wissen S.
        • Wollersheim H.
        • Trip M.D.
        • Kastelein J.J.
        • Stalenhoef A.F.
        Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial.
        Lancet. 2001; 357: 577-581
      3. Cohen JD, Cziraky MJ, Jacobson TA, Wallace A, Cai C. Changes in the prevalence of abnormal lipid fractions among US adults: results from the National Health and Nutrition Examination Survey II, III, and 1999–2006. Abstract 1189. Presented at the Abstracts of Scientific Sessions 2008; New Orleans, Louisiana; October 28, 2008.

        • Dluhy R.G.
        • McMahon G.T.
        Intensive glycemic control in the ACCORD and ADVANCE trials.
        N Engl J Med. 2008; 358: 2630-2633
        • Ridker P.M.
        • Rifai N.
        • Clearfield M.
        • Downs J.R.
        • Weis S.E.
        • Miles J.S.
        • Gotto Jr, A.M.
        • Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators
        Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.
        N Engl J Med. 2001; 344: 1959-1965
        • Ridker P.M.
        • Danielson E.
        • Fonseca F.A.
        • Genest J.
        • Gotto Jr, A.M.
        • Kastelein J.J.
        • Koenig W.
        • Libby P.
        • Lorenzatti A.J.
        • MacFadyen J.G.
        • Nordestgaard B.G.
        • Shepherd J.
        • Willerson J.T.
        • Glynn R.J.
        • JUPITER Study Group
        Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
        N Engl J Med. 2008; 359: 2195-2207
        • Pearson T.A.
        • Mensah G.A.
        • Alexander R.W.
        • Anderson J.L.
        • Cannon III, R.O.
        • Criqui M.
        • Fadl Y.Y.
        • Fortmann S.P.
        • Hong Y.
        • Myers G.L.
        • Rifai N.
        • Smith Jr, S.C.
        • Taubert K.
        • Tracy R.P.
        • Vinicor F.
        • Centers for Disease Control and Prevention, American Heart Association, Centers for Disease Control and Prevention; American Heart Association
        Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.
        Circulation. 2003; 107: 499-511
        • Ridker P.M.
        • Cannon C.P.
        • Morrow D.
        • Rifai N.
        • Rose L.M.
        • McCabe C.H.
        • Pfeffer M.A.
        • Braunwald E.
        • Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators
        C-reactive protein levels and outcomes after statin therapy.
        N Engl J Med. 2005; 352: 20-28
        • Ray K.K.
        • Cannon C.P.
        • Cairns R.
        • Morrow D.A.
        • Ridker P.M.
        • Braunwald E.
        Prognostic utility of ApoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes results from PROVE IT–TIMI 22.
        Arterioscler Thromb Vasc Biol. 2009; 29: 424-430
        • Bansal S.
        • Ridker P.M.
        Comparison of characteristics of future myocardial infarctions in women with baseline high versus baseline low levels of high-sensitivity C-reactive protein.
        Am J Cardiol. 2007; 99: 1500-1503
        • Cook N.R.
        • Buring J.E.
        • Ridker P.M.
        The effect of including C-reactive protein in cardiovascular risk prediction models for women.
        Ann Intern Med. 2006; 145: 21-29
        • Albert M.A.
        • Glynn R.J.
        • Ridker P.M.
        Plasma concentration of C-reactive protein and the calculated Framingham coronary heart disease risk score.
        Circulation. 2003; 108: 161-165
        • Hecht H.S.
        • Budoff M.J.
        • Berman D.S.
        • Ehrlich J.
        • Rumberger J.A.
        Coronary artery calcium scanning: clinical paradigms for cardiac risk assessment and treatment.
        Am Heart J. 2006; 151: 1139-1146
        • Robinson J.G.
        • Smith B.
        • Maheshwari N.
        • Schrott H.
        Pleiotropic effects of statins: benefit beyond cholesterol reduction?.
        J Am Coll Cardiol. 2005; 46: 1855-1862
        • Baigent C.
        • Keech A.
        • Kearney P.M.
        • Blackwell L.
        • Buck G.
        • Pollicino C.
        • Kirby A.
        • Sourjina T.
        • Peto R.
        • Collins R.
        • Simes R.
        • Cholesterol Treatment Trialists (CTT) Collaborators
        Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
        Lancet. 2005; 366: 1267-1278
        • Rossebø A.B.
        • Pedersen T.R.
        • Boman K.
        • Brudi P.
        • Chambers J.B.
        • Egstrup K.
        • Gerdts E.
        • Gohlke-Bärwolf C.
        • Holme I.
        • Kesäniemi Y.A.
        • Malbecq W.
        • Nienaber C.A.
        • Ray S.
        • Skjaerpe T.
        • Wachtell K.
        • Willenheimer R.
        • SEAS Investigators
        Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
        N Engl J Med. 2008; 359: 1343-1356
        • Kastelein J.J.
        • Akdim F.
        • Stroes E.S.
        • Zwinderman A.H.
        • Bots M.L.
        • Stalenhoef A.F.
        • Visseren F.L.
        • Sijbrands E.J.
        • Trip M.D.
        • Stein E.A.
        • Gaudet D.
        • Duivenvoorden R.
        • Veltri E.P.
        • Marais A.D.
        • de Groot E.
        • ENHANCE Investigators
        Simvastatin with or without ezetimibe in familial hypercholesterolemia.
        N Engl J Med. 2008; 358: 1431-1443
        • Fleg J.L.
        • Mete M.
        • Howard B.V.
        • Umans J.G.
        • Roman M.J.
        • Ratner R.E.
        • Silverman A.
        • Galloway J.M.
        • Henderson J.A.
        • Weir M.R.
        • Wilson C.
        • Stylianou M.
        • Howard W.J.
        Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial.
        J Am Coll Cardiol. 2008; 52: 2198-2205
        • Kane J.P.
        • Malloy M.J.
        • Ports T.A.
        • Phillips N.R.
        • Diehl J.C.
        • Havel R.J.
        Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.
        JAMA. 1990; 264: 3007-3012
      4. IMPROVE-IT: examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin.
        (Accessed December 29, 2008)
      5. SHARP: Study of Heart and Renal Protection.
        (Accessed December 29, 2008)
        • Chambless L.E.
        • Heiss G.
        • Folsom A.R.
        • Rosamond W.
        • Szklo M.
        • Sharrett A.R.
        • Clegg L.X.
        Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993.
        Am J Epidemiol. 1997; 146: 483-494
        • Bots M.L.
        • Hoes A.W.
        • Koudstaal P.J.
        • Horman A.
        • Grobbee D.E.
        Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study.
        Circulation. 1997; 96: 1432-1437
        • Hodis H.N.
        • Mack W.J.
        • LaBree L.
        • Selzer R.H.
        • Liu C.R.
        • Liu C.H.
        • Azen S.P.
        The role of carotid arterial intima-media thickness in predicting clinical coronary events.
        Ann Intern Med. 1998; 128: 262-269
        • Jacobson T.A.
        Statin safety: lessons from new drug applications for marketed statins.
        Am J Cardiol. 2006; 97: 44C-51C
        • Golomb B.A.
        • Evans M.A.
        Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism.
        Am J Cardiovasc Drugs. 2008; 8: 373-418
        • Bruckert E.
        • Hayem G.
        • Dejager S.
        • Yau C.
        • Bégaud B.
        Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study.
        Cardiovasc Drugs Ther. 2005; 19: 403-414
        • McKenney J.M.
        • Davidson M.H.
        • Jacobson T.A.
        • Guyton J.R.
        • National Lipid Association Statin Safety Assessment Task Force
        Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.
        Am J Cardiol. 2006; 97: 89C-94C
        • Sacks F.M.
        • Pfeffer M.A.
        • Moye L.A.
        • Rouleau J.L.
        • Rutherford J.D.
        • Cole T.G.
        • Brown L.
        • Warnica J.W.
        • Arnold J.M.
        • Wun C.C.
        • Davis B.R.
        • Braunwald E.
        The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
        N Engl J Med. 1996; 335: 1001-1009
        • Dale K.M.
        • Coleman C.I.
        • Henyan N.N.
        • Kluger J.
        • White C.M.
        Statins and cancer risk: a meta-analysis.
        JAMA. 2006; 295: 74-80
        • Alsheikh-Ali A.A.
        • Maddukuri P.V.
        • Han H.
        • Karas R.H.
        Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials.
        J Am Coll Cardiol. 2007; 50: 409-418
        • Alsheikh-Ali A.A.
        • Trikalinos T.A.
        • Kent D.M.
        • Karas R.H.
        Statins, low-density lipoprotein cholesterol, and risk of cancer.
        J Am Coll Cardiol. 2008; 52: 1141-1147
        • Ridker P.M.
        • Danielson E.
        • Fonseca F.A.
        • Genest J.
        • Gotto Jr., A.M.
        • Kastelein J.J.
        • Koenig W.
        • Libby P.
        • Lorenzatti A.J.
        • Nordestgaard B.G.
        • Shepherd J.
        • Willerson J.T.
        • Glynn R.J.
        • JUPITER Study Group
        Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
        N Engl J Med. 2008; 359: 2195-2207
        • Jacobson T.A.
        • Armani A.
        • McKenney J.M.
        • Guyton J.R.
        Safety considerations with gastrointestinally active lipid-lowering drugs.
        Am J Cardiol. 2007; 99: 47C-55C
        • Zhao Z.
        • Tuakli-Wosornu Y.
        • Lagace T.A.
        • Kinch L.
        • Grishin N.V.
        • Horton J.D.
        • Cohen J.C.
        • Hobbs H.H.
        Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote.
        Am J Hum Genet. 2006; 79: 514-523
        • Downs J.R.
        • Clearfield M.
        • Weis S.
        • Whitney E.
        • Shapiro D.R.
        • Beere P.A.
        • Langendorfer A.
        • Stein E.A.
        • Kruyer W.
        • Gotto Jr, A.M.
        Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS.
        JAMA. 1998; 279: 1615-1622
        • Kastelein J.J.
        • van Leuven S.I.
        • Burgess L.
        • Evans G.W.
        • Kuivenhoven J.A.
        • Barter P.J.
        • Revkin J.H.
        • Grobbee D.E.
        • Riley W.A.
        • Shear C.L.
        • RADIANCE 1 Investigators
        Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
        N Engl J Med. 2007; 356: 1620-1630
        • Nissen S.E.
        • Tardif J.C.
        • Nicholls S.J.
        • Revkin J.H.
        • Shear C.L.
        • Duggan W.T.
        • Ruzyllo W.
        • Bachinsky W.B.
        • Lasala G.P.
        • Tuzcu E.M.
        • ILLUSTRATE Investigators
        Effect of torcetrapib on the progression of coronary atherosclerosis.
        N Engl J Med. 2007; 356: 1304-1316
        • Barter P.J.
        • Caulfield M.
        • Eriksson M.
        • Grundy S.M.
        • Kastelein J.J.
        • Komajda M.
        • Lopez-Sendon J.
        • Mosca L.
        • Tardif J.C.
        • Waters D.D.
        • Shear C.L.
        • Revkin J.H.
        • Buhr K.A.
        • Fisher M.R.
        • Tall A.R.
        • Brewer B.
        • ILLUMINATE Investigators
        Effects of torcetrapib in patients at high risk for coronary events.
        N Engl J Med. 2007; 357: 2109-2122
      6. Study to assess the tolerability and efficacy of anacetrapib in patients with coronary heart disease (CHD) or CHD risk-equivalent disease (DEFINE).
        (Accessed December 17, 2008)
      7. JTT-705 studies.
        (Accessed December 17, 2008)
        • The Coronary Drug Project Research Group
        Clofibrate and niacin in coronary heart disease.
        JAMA. 1975; 231: 360-381
        • Canner P.L.
        • Berge K.G.
        • Wenger N.K.
        • Stamler J.
        • Friedman L.
        • Prineas R.J.
        • Friedewald W.
        Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.
        J Am Coll Cardiol. 1986; 8: 1245-1255
        • Carlson L.
        • Rosenhamer G.
        Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid.
        Acta Med Scand. 1988; 223: 405-418
        • Brown B.G.
        • Zhao X.Q.
        • Chait A.
        • Fisher L.D.
        • Cheung M.C.
        • Morse J.S.
        • Dowdy A.A.
        • Marino E.K.
        • Bolson E.L.
        • Alaupovic P.
        • Frohlich J.
        • Albers J.J.
        Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
        N Engl J Med. 2001; 345: 1583-1592
        • Taylor A.J.
        • Villines T.C.
        • Stanek E.J.
        • Devine P.J.
        • Griffen L.
        • Miller M.
        • Weissman N.J.
        • Turco M.
        Extended-release niacin or ezetimibe and carotid intima-media thickness.
        N Engl J Med. 2009; 361: 2113-2122
        • Whitney E.J.
        • Krasuski R.A.
        • Personius B.E.
        • Michalek J.E.
        • Maranian A.M.
        • Kolasa M.W.
        • Monick E.
        • Brown B.G.
        • Gotto Jr, A.M.
        A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events.
        Ann Intern Med. 2005; 142: 95-104
      8. AIM HIGH: Niacin plus statin to prevent vascular events.
        • HPS2-THRIVE
        Treatment of HDL to reduce the incidence of vascular events.
        • Guyton J.R.
        • Bays H.E.
        Safety considerations with niacin therapy.
        Am J Cardiol. 2007; 99: S22-S31
        • Maccubbin D.
        • Bays H.E.
        • Olsson A.G.
        • Elinoff V.
        • Elis A.
        • Mitchel Y.
        • Sirah W.
        • Betteridge A.
        • Reyes R.
        • Yu Q.
        • Kuznetsova O.
        • Sisk C.M.
        • Pasternak R.C.
        • Paolini J.F.
        Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
        Int J Clin Pract. 2008; 62: 1959-1970